Matrix-integrated microfluidic tumor models for evaluating drug delivery systems and pre-clinical testing.
3/5 보강
TL;DR
This review highlights emerging computational and data-driven approaches, together with current translational and regulatory perspectives, that position matrix-integrated tumor-on-chip technologies as powerful preclinical tools that aim to bridge the gap between simplified in vitro assays and more complex in vivo studies.
OpenAlex 토픽 ·
3D Printing in Biomedical Research
Cancer Cells and Metastasis
Nanoparticle-Based Drug Delivery
This review highlights emerging computational and data-driven approaches, together with current translational and regulatory perspectives, that position matrix-integrated tumor-on-chip technologies as
APA
Paula Guerrero-López, Pilar Alamán-Díez, et al. (2026). Matrix-integrated microfluidic tumor models for evaluating drug delivery systems and pre-clinical testing.. Advanced drug delivery reviews, 232, 115836. https://doi.org/10.1016/j.addr.2026.115836
MLA
Paula Guerrero-López, et al.. "Matrix-integrated microfluidic tumor models for evaluating drug delivery systems and pre-clinical testing.." Advanced drug delivery reviews, vol. 232, 2026, pp. 115836.
PMID
41724330 ↗
Abstract 한글 요약
Drug delivery research strongly depends on experimental models that faithfully mimic the tumor microenvironment (TME) and its barriers to evaluate therapeutic efficacy. Conventional systems provide valuable insights but suffer from some limitations in physiological relevance, reproducibility, scalability or translational predictability. In this context, microfluidic 'tumor-on-chip' platforms have emerged as innovative tools that integrate engineering technology to model biological complexity, offering controlled microenvironments to investigate drug penetration, transport dynamics, and therapeutic response. A distinctive aspect of these microsystems is the possibility of incorporating matrices that mimic the extracellular matrix (ECM) of different tissues. These matrices enhance the ability of the in vitro models to replicate the structural, biochemical, and mechanical features of solid tumors. In this review, we focus on the application of microfluidic matrix-integrated tumor-on-chip platforms for drug delivery evaluation. We first outline key microenvironmental features that regulate therapeutic efficacy and discuss how they can be engineered within microfluidic models. We then examine how transport dynamics and delivery mechanisms are modeled under physiologically relevant conditions and review the use of these platforms to assess a broad range of therapeutic strategies, including nanocarriers, biologics, and gene- and cell-based therapies. Finally, we highlight emerging computational and data-driven approaches, together with current translational and regulatory perspectives, that position matrix-integrated tumor-on-chip technologies as powerful preclinical tools. These models aim to bridge the gap between simplified in vitro assays and more complex in vivo studies, ultimately accelerating the translation of drug delivery systems into clinical practice and paving the way for more personalized therapeutic strategies.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (1)
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.